
EMA recommends to continue AZD1222 vaccinations
After the stops of AstraZeneca's COVID-19 vaccine or specific batches of it in 13 EU member states, the EU regulatory authority EMA has analysed the...

Roche in take-over deal with GenMark Diagnostics
The US$1.8bn cash merger – US$ 24.05 per share – is set to close in Q2/2021. The price represents a premium of approximately 43% to GenMark’s...

Next-gen COVID-19 vaccine good in preclinical tests
In contrast to injectable vaccines, the nasal jab seems capablet to induce mucosal immunity which is crucial to eliminate the virus instead only...

German researchers find reason for remdesivir's inefficiency
“We have come to a simple conclusion,” said Max Planck Director Patrick Cramer at the MPI for Biophysical Chemistry. “Remdesivir does interfere with...

Novel COVID antibody enters clinical testing
In contrast to existing COVID-19 treatments, the safety design of COR-101 is optimised for the treatment of hospitalized COVID-19 patients with...

Immunocore bags US$75m in Series C round
The round included support from existing investors and funds and accounts managed by BlackRock. Immunocore said it will use the proceeds to ...

Roche Phase III study misses COVID-19 endpoint
In the Phase III REMDACTA trial, the Swiss pharma major combined its cytokine storm blocker tocolizumab with Gilead Science’s viral transcription...